# Inhibition of Bradykinin in COVID-19 Infection With Icatibant

> **NCT05407597** · PHASE2,PHASE3 · COMPLETED · sponsor: **Belfast Health and Social Care Trust** · enrollment: 32 (actual)

## Conditions studied

- SARS CoV 2 Infection

## Interventions

- **DRUG:** Icatibant
- **DRUG:** 0.9% Sodium Chloride Injection

## Key facts

- **NCT ID:** NCT05407597
- **Lead sponsor:** Belfast Health and Social Care Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-16
- **Primary completion:** 2023-06-09
- **Final completion:** 2023-07-07
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2023-09-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05407597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05407597, "Inhibition of Bradykinin in COVID-19 Infection With Icatibant". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05407597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*